Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care

TheBenchMark ULTRA PLUS tissue staining system, withoptimised workflow, testing efficiency and environmentally sustainable features, enables pathologists to provide high-quality, time-critical results to doctors and patients.With laboratory diagnostics involved in more than two-thirds of healthcaredecision making, innovative laboratory solutions that enable an accurate and timely diagnosis are crucial to successful treatment.About 17 million new cases of cancer are diagnosed worldwide each year, and nearly 10 million people die from the disease.1Basel, 29 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the BenchMark ULTRA PLUS system, its newest advanced tissue staining platform. The system enables quick and accurate test results so clinicians can make timely decisions regarding a patient ’s care journey.“With the BenchMark ULTRA PLUS, we are pleased to offer an advanced tissue staining platform, co-developed with lab professionals,” said Thomas Schinecker, CEO of Roche Diagnostics. “Waiting for a diagnosis is often one of the most stressful times for patients. This system enables pathologists to provide quick and accurate results that help inform patient treatment options.”Cancer and other abnormal cells can be characterised by biochemical markers from within the cells. By applying chemical solutions to tissue on glass slides with the BenchMark ULTRA PLUS, a healthcare professional can identify these markers to determine the presence or...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news